ArticleMolecular oncology2023

ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.

Jessica W Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.